{
  "guideline": {
    "id": "PA166104839",
    "name": "Annotation of FDA Label for aripiprazole and CYP2D6",
    "source": "FDA",
    "version": 32,
    "url": "https://www.pharmgkb.org/labelAnnotation/PA166104839",
    "relatedChemicals": [
      {
        "id": "PA10026",
        "name": "aripiprazole",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA128",
        "name": "cytochrome P450 family 2 subfamily D member 6",
        "symbol": "CYP2D6"
      }
    ],
    "recommendation": false
  },
  "recommendations": [
    {
      "id": "PA166312183",
      "name": "Recommendation Annotation PA166312183",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA10026",
          "name": "aripiprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216422,
        "html": "<p>The ABILIFY label states, &quot;Dosage adjustments are recommended in patients who are known CYP2D6 poor metabolizers.&quot; For known CYP2D6 poor metabolizers, administer half of usual dose. For known CYP2D6 poor metabolizers taking concomitant strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin), administer a quarter of usual dose. The ABILIFY MAINTENA label states, &quot;Known CYP2D6 poor metabolizers: Recommended starting and maintenance dose is 300 mg administered monthly as a single injection.&quot; For known CYP2D6 poor metabolizers taking concomitant CYP3A4 inhibitors, recommended dose is 200 mg. See labels for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "0.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": null,
      "title": "Drugs@FDA: Drug Product ABILIFY (ARIPIPRAZOLE), NDA021436, Rebel Distributors Corp.",
      "authors": [],
      "journal": null,
      "year": -1,
      "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021436"
    },
    {
      "pmid": null,
      "title": "Drugs@FDA: Drug Product ABILIFY MAINTENA (aripiprazole), NDA202971, Otsuka America Pharmaceutical, Inc.",
      "authors": [],
      "journal": null,
      "year": -1,
      "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202971"
    }
  ],
  "version": "2024-02-29-20-19"
}